ScoreWhy is Chengdu Olymvax Biopharmaceuticals, Inc. ?
1
With a growth in Net Sales of 25.38%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 6.86%
- INTEREST COVERAGE RATIO(Q) Highest at 1,289.5
- RAW MATERIAL COST(Y) Fallen by -2.66% (YoY)
2
Market Beating performance in long term as well as near term
- Along with generating 103.83% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Chengdu Olymvax Biopharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Chengdu Olymvax Biopharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Chengdu Olymvax Biopharmaceuticals, Inc.
93.51%
2.70
63.41%
China Shanghai Composite
19.02%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.39%
EBIT Growth (5y)
-4.86%
EBIT to Interest (avg)
15.30
Debt to EBITDA (avg)
0.61
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.47
Tax Ratio
15.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.29%
ROE (avg)
4.40%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
202
Industry P/E
Price to Book Value
13.23
EV to EBIT
176.00
EV to EBITDA
125.41
EV to Capital Employed
11.39
EV to Sales
18.15
PEG Ratio
0.38
Dividend Yield
NA
ROCE (Latest)
6.47%
ROE (Latest)
6.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 104.13 MM
PRE-TAX PROFIT(Q)
At CNY 32.42 MM has Grown at 560.44%
NET PROFIT(Q)
At CNY 27.19 MM has Grown at 484.36%
NET SALES(Q)
At CNY 157.8 MM has Grown at 80.37%
RAW MATERIAL COST(Y)
Fallen by -6.88% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 1.03 times
DEBTORS TURNOVER RATIO(HY)
Highest at 1.22 times
-7What is not working for the Company
NET PROFIT(HY)
At CNY 1.97 MM has Grown at -79.61%
DEBT-EQUITY RATIO
(HY)
Highest at 25.79 %
INTEREST(Q)
Highest at CNY 4.12 MM
Here's what is working for Chengdu Olymvax Biopharmaceuticals, Inc.
Pre-Tax Profit
At CNY 32.42 MM has Grown at 560.44%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 27.19 MM has Grown at 484.36%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 104.13 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
At CNY 157.8 MM has Grown at 80.37%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CNY MM)
Inventory Turnover Ratio
Highest at 1.03 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 1.22 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -6.88% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Chengdu Olymvax Biopharmaceuticals, Inc.
Debt-Equity Ratio
Highest at 25.79 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Interest
Highest at CNY 4.12 MM
in the last five periods and Increased by 7.6% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
